Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Medexus Pharmaceuticals Inc (MDP.TO)
Medexus Pharmaceuticals Inc (MDP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 39,133
  • Shares Outstanding, K 24,458
  • Annual Sales, $ 108,096 K
  • Annual Income, $ 1,221 K
  • 60-Month Beta 2.09
  • Price/Sales 0.21
  • Price/Cash Flow 1.86
  • Price/Book 1.33
Trade MDP.TO with:
  • Price/Earnings ttm 4.74
  • Earnings Per Share ttm 0.25
  • Most Recent Earnings -0.05 on N/A
  • Next Earnings Date 12/05/23
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate 0.02
  • Number of Estimates 4
  • High Estimate 0.13
  • Low Estimate -0.09
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +110.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.44 +7.64%
on 12/04/23
2.19 -29.22%
on 11/07/23
-0.58 (-27.23%)
since 11/03/23
3-Month
1.44 +7.64%
on 12/04/23
3.47 -55.33%
on 09/12/23
-1.58 (-50.48%)
since 09/05/23
52-Week
1.12 +38.39%
on 06/09/23
3.53 -56.09%
on 08/24/23
-0.63 (-28.90%)
since 12/05/22

Most Recent Stories

More News
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday,...

MEDXF : 1.1800 (+0.37%)
MDP.TO : 1.55 (-3.13%)
Stocks in play: Medexus Pharmaceuticals

Plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, to discuss Medexus's ...

MDP.TO : 1.55 (-3.13%)
Medexus Schedules Second Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November...

MEDXF : 1.1800 (+0.37%)
MDP.TO : 1.55 (-3.13%)
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal...

MDP.TO : 1.55 (-3.13%)
Medexus Fully Repays Convertible Debentures In Cash At Maturity

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately...

MDP.TO : 1.55 (-3.13%)
Medexus Announces Closing of C$10 Million Bought-Deal Public Offering

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900...

MDP.TO : 1.55 (-3.13%)
Medexus and medac Agree to Amend US Treosulfan Agreement

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment...

MDP.TO : 1.55 (-3.13%)
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

All director nominees reelected and all other company proposals approved by shareholdersToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP)...

MEDXF : 1.1800 (+0.37%)
MDP.TO : 1.55 (-3.13%)
Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility

Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. -...

MEDXF : 1.1800 (+0.37%)
MDP.TO : 1.55 (-3.13%)
Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B

Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent safety profilePhase 3/4 data...

MDP.TO : 1.55 (-3.13%)
MEDXF : 1.1800 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 1.85
2nd Resistance Point 1.73
1st Resistance Point 1.67
Last Price 1.55
1st Support Level 1.49
2nd Support Level 1.37
3rd Support Level 1.31

See More

52-Week High 3.53
Fibonacci 61.8% 2.61
Fibonacci 50% 2.33
Fibonacci 38.2% 2.04
Last Price 1.55
52-Week Low 1.12

See More

Business Summary

Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar